|
1
|
Griffiths TR; Action on Bladder Cancer, :
Current perspectives in bladder cancer management. Int J Clin
Pract. 67:435–448. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pastorelli R, Saletta F, Carpi D, Campagna
R, del l'Osta C, Schiarea S, Vineis P, Airoldi L and Matullo G:
Proteome characterization of a human urothelial cell line resistant
to the bladder carcinogen 4-aminobiphenyl. Proteome Sci. 5:62007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gu S, Jin L, Zhang F, Sarnow P and Kay MA:
Biological basis for restriction of microRNA targets to the 3′
untranslated region in mammalian mRNAs. Nat Struct Mol Biol.
16:144–150. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP and Chen CZ: Micromanagers of
gene expression: The potentially widespread influence of metazoan
microRNAs. Nat Rev Genet. 5:396–400. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nicoloso MS, Spizzo R, Shimizu M, Rossi S
and Calin GA: MicroRNAs-the micro steering wheel of tumour
metastases. Nat Rev Cancer. 9:293–302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adlakha YK and Saini N: Brain microRNAs
and insights into biological functions and therapeutic potential of
brain enriched miRNA-128. Mol Cancer. 13:332014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
He Y, Lin J, Kong D, Huang M, Xu C, Kim
TK, Etheridge A, Luo Y, Ding Y and Wang K: Current State of
circulating MicroRNAs as cancer biomarkers. Clin Chem.
61:1138–1155. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chawla JP, Iyer N, Soodan KS, Sharma A,
Khurana SK and Priyadarshni P: Role of miRNA in cancer diagnosis,
prognosis, therapy and regulation of its expression by Epstein-Barr
virus and human papillomaviruses: With special reference to oral
cancer. Oral Oncol. 51:731–737. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Andrew AS, Marsit CJ, Schned AR, Seigne
JD, Kelsey KT, Moore JH, Perreard L, Karagas MR and Sempere LF:
Expression of tumor suppressive microRNA-34a is associated with a
reduced risk of bladder cancer recurrence. Int J Cancer.
137:1158–1166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bandres E, Agirre X, Ramirez N, Zarate R
and Garcia-Foncillas J: MicroRNAs as cancer players: Potential
clinical and biological effects. DNA Cell Biol. 26:273–282. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Catto JW, Miah S, Owen HC, Bryant H, Myers
K, Dudziec E, Larré S, Milo M, Rehman I, Rosario DJ, et al:
Distinct microRNA alterations characterize high- and low-grade
bladder cancer. Cancer Res. 69:8472–8481. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pignot G, Cizeron-Clairac G, Vacher S,
Susini A, Tozlu S, Vieillefond A, Zerbib M, Lidereau R, Debre B,
Amsellem-Ouazana D and Bieche I: microRNA expression profile in a
large series of bladder tumors: Identification of a 3-miRNA
signature associated with aggressiveness of muscle-invasive bladder
cancer. Int J Cancer. 132:2479–2491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gottardo F, Liu CG, Ferracin M, Calin GA,
Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, et
al: Micro-RNA profiling in kidney and bladder cancers. Urol Oncol.
25:387–392. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hidaka H, Seki N, Yoshino H, Yamasaki T,
Yamada Y, Nohata N, Fuse M, Nakagawa M and Enokida H: Tumor
suppressive microRNA-1285 regulates novel molecular targets:
Aberrant expression and functional significance in renal cell
carcinoma. Oncotarget. 3:44–57. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoshino H, Seki N, Itesako T, Chiyomaru T,
Nakagawa M and Enokida H: Aberrant expression of microRNAs in
bladder cancer. Nat Rev Urol. 10:396–404. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cao R, Meng Z, Liu T, Wang G, Qian G, Cao
T, Guan X, Dan H, Xiao Y and Wang X: Decreased TRPM7 inhibits
activities and induces apoptosis of bladder cancer cells via ERK1/2
pathway. Oncotarget. 7:72941–72960. 2016.PubMed/NCBI
|
|
18
|
Chen L, Wang G, Luo Y, Wang Y, Xie C,
Jiang W, Xiao Y, Qian G and Wang X: Downregulation of LAPTM5
suppresses cell proliferation and viability inducing cell cycle
arrest at G0/G1 phase of bladder cancer cells. Int J Oncol.
50:263–271. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang G, Cao R, Wang Y, Qian G, Dan HC,
Jiang W, Ju L, Wu M, Xiao Y and Wang X: Simvastatin induces cell
cycle arrest and inhibits proliferation of bladder cancer cells via
PPARgamma signalling pathway. Sci Rep. 6:357832016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tusher VG, Tibshirani R and Chu G:
Significance analysis of microarrays applied to the ionizing
radiation response. Proc Natl Acad Sci USA. 98:pp. 5116–5121. 2001;
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chu G, Seo M, Li J, Narasimhan B,
Tibshirani R and Tusher V: SAM: Significance Analysis of
Microarrays. Users Guide and technical document. http://statweb.stanford.edu/~tibs/SAM/sam.pdf
|
|
22
|
Storey JD: A direct approach to false
discovery rates. J Roy Stat Soc Ser. 64:479–498. 2002. View Article : Google Scholar
|
|
23
|
Li T, Pan H and Li R: The dual regulatory
role of miR-204 in cancer. Tumour Biol. 37:11667–11677. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang G, Xiong G, Cao Z, Zheng S, You L,
Zhang T and Zhao Y: miR-497 expression, function and clinical
application in cancer. Oncotarget. 7:55900–55911. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Y, Zhang X, Li H, Yu J and Ren X: The
role of miRNA-29 family in cancer. Eur J Cell Biol. 92:123–128.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang X, Wu Q, Xu B, Wang P, Fan W, Cai Y,
Gu X and Meng F: MiR-124 exerts tumor suppressive functions on the
cell proliferation, motility and angiogenesis of bladder cancer by
fine-tuning UHRF1. FEBS J. 282:4376–4388. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shaham L, Binder V, Gefen N, Borkhardt A
and Izraeli S: miR-125 in normal and malignant hematopoiesis.
Leukemia. 26:2011–2018. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li S, Xu X, Xu X, Hu Z, Wu J, Zhu Y, Chen
H, Mao Y, Lin Y, Luo J, et al: MicroRNA-490-5p inhibits
proliferation of bladder cancer by targeting c-Fos. Biochem Biophys
Res Commun. 441:976–981. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yonemori M, Seki N, Yoshino H, Matsushita
R, Miyamoto K, Nakagawa M and Enokida H: Dual tumor-suppressors
miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in
bladder cancer. Cancer Sci. 107:1233–1242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, Yin
C and Zhang W: microRNA-133 inhibits cell proliferation, migration
and invasion in prostate cancer cells by targeting the epidermal
growth factor receptor. Oncol Rep. 27:1967–1975. 2012.PubMed/NCBI
|
|
31
|
Kou B, Gao Y, Du C, Shi Q, Xu S, Wang CQ,
Wang X, He D and Guo P: miR-145 inhibits invasion of bladder cancer
cells by targeting PAK1. Urol Oncol. 32:846–854. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yoshino H, Chiyomaru T, Enokida H,
Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N and Nakagawa
M: The tumour-suppressive function of miR-1 and miR-133a targeting
TAGLN2 in bladder cancer. Br J Cancer. 104:808–818. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pierzynski JA, Hildebrandt MA, Kamat AM,
Lin J, Ye Y, Dinney CP and Wu X: Genetic Variants in the
Wnt/β-Catenin signaling pathway as indicators of bladder cancer
risk. J Urol. 194:1771–1776. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee SJ, Lim JH, Choi YH, Kim WJ and Moon
SK: Interleukin-28A triggers wound healing migration of bladder
cancer cells via NF-κB-mediated MMP-9 expression inducing the MAPK
pathway. Cell Signal. 24:1734–1742. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pawlak G, McGarvey TW, Nguyen TB,
Tomaszewski JE, Puthiyaveettil R, Malkowicz SB and Helfman DM:
Alterations in tropomyosin isoform expression in human transitional
cell carcinoma of the urinary bladder. Int J Cancer. 110:368–373.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Park SY, Kim H, Yoon S, Bae JA, Choi SY,
Jung YD and Kim KK: KITENIN-targeting microRNA-124 suppresses
colorectal cancer cell motility and tumorigenesis. Mol Ther.
22:1653–1664. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Oh HH, Park KJ, Kim N, Park SY, Park YL,
Oak CY, Myung DS, Cho SB, Lee WS, Kim KK and Joo E: Impact of
KITENIN on tumor angiogenesis and lymphangiogenesis in colorectal
cancer. Oncol Rep. 35:253–260. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
XM, Zhu HY, Bai WD, Wang T, Wang L, Chen
Y, Yang AG and Jia LT: Epigenetic silencing of miR-375 induces
trastuzumab resistance in HER2-positive breast cancer by targeting
IGF1R. BMC Cancer. 14:1342014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Taliaferro-Smith L, Oberlick E, Liu T,
McGlothen T, Alcaide T, Tobin R, Donnelly S, Commander R, Kline E,
Nagaraju GP, et al: FAK activation is required for IGF1R-mediated
regulation of EMT, migration, and invasion in mesenchymal triple
negative breast cancer cells. Oncotarget. 6:4757–4772. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nagalingam RS, Sundaresan NR, Gupta MP,
Geenen DL, Solaro RJ and Gupta M: A cardiac-enriched microRNA,
miR-378, blocks cardiac hypertrophy by targeting Ras signaling. J
Biol Chem. 288:11216–11232. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Huang AH, Pan SH, Chang WH, Hong QS, Chen
JJ and Yu SL: PARVA promotes metastasis by modulating ILK
signalling pathway in lung adenocarcinoma. PLoS One.
10:e01185302015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang Y, Zhang Z, Li Z, Gong D, Zhan B,
Man X and Kong C: MicroRNA-497 inhibits the proliferation,
migration and invasion of human bladder transitional cell carcinoma
cells by targeting E2F3. Oncol Rep. 36:1293–1300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Du M, Shi D, Yuan L, Li P, Chu H, Qin C,
Yin C, Zhang Z and Wang M: Circulating miR-497 and miR-663b in
plasma are potential novel biomarkers for bladder cancer. Sci Rep.
5:104372015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chiyomaru T, Enokida H, Tatarano S,
Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N
and Nakagawa M: miR-145 and miR-133a function as tumour suppressors
and directly regulate FSCN1 expression in bladder cancer. Br J
Cancer. 102:883–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Avgeris M, Mavridis K, Tokas T,
Stravodimos K, Fragoulis EG and Scorilas A: Uncovering the clinical
utility of miR-143, miR-145 and miR-224 for predicting the survival
of bladder cancer patients following treatment. Carcinogenesis.
36:528–537. 2015. View Article : Google Scholar : PubMed/NCBI
|
